Related Experiment Video
Updated: Feb 21, 2026
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
Subcutaneous Autologous Serum Therapy in Chronic Spontaneous Urticaria
Kiran Vasant Godse1, Nitin Nadkarni1, Sharmila Patil1
1Department of Dermatology, D. Y. Patil Hospital, Navi Mumbai, Maharashtra, India.
Background:
There is a felt need for trying newer therapeutic modalities in patients with chronic spontaneous urticaria, especially in the subset of patients classified as non-responders to antihistamines. Autologous serum therapy is an upcoming modality of treatment, and we decided to study its efficacy by subcutaneous route.
Aims:
To evaluate the effectiveness of subcutaneous autologous serum therapy (AST) in CSU.
Methods:
This was a single blind, placebo-controlled parallel group, randomized, controlled study. Twenty-four patients with CSU (11M: 13 F) were given subcutaneous AST and seventeen patients (7 M: 10F) patients were given subcutaneous injection normal saline (placebo), along with levocetirizine in an on-demand basis in both groups.
Results:
Urticaria activity score (UAS) came down from 35.74 to 7 at the end of 9 weeks and the patients' requirement of antihistamines also reduced remarkably from 5.8 to 1.7 per week in the serum group. Sub-cutaneous saline group did not show statistically significant fall in UAS. Saline group showed UAS 32.8 at zero week to 22.1 at the end of 9 weeks. DLQI showed significant fall in serum group, from 14.26 to 4 at the end of 9 weeks.
Conclusion:
Subcutaneous autoserum therapy is effective in treatment of CSU.
